Growth Metrics

Alnylam Pharmaceuticals (ALNY) Current Deferred Tax Assets (2009 - 2010)

Alnylam Pharmaceuticals posted quarterly Current Deferred Tax Assets of $1.9 million for Q3 2010, little changed on a QoQ basis from $1.9 million in Q2 2010.

Alnylam Pharmaceuticals (ALNY) has 2 years of Current Deferred Tax Assets data on file, last reported at $1.9 million in Q3 2010.

  • For the quarter ending Q3 2010, Current Deferred Tax Assets changed N/A year-over-year to $1.9 million; the trailing twelve-month figure through Sep 2010 stood at $1.9 million (changed N/A YoY), and the FY2009 full-year result was $1.9 million, changed N/A from the prior year.
  • Current Deferred Tax Assets for Q3 2010 stood at $1.9 million, roughly flat from $1.9 million in the prior quarter.
  • Across five years, Current Deferred Tax Assets topped out at $1.9 million in Q3 2010 and bottomed at $1.9 million in Q4 2009.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Revolution Medicines 32.39 Bn 32.39 Bn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2010 1.94 Mn
Sep 30, 2010 1.94 Mn
Jun 30, 2010 1.94 Mn
Jun 30, 2010 1.94 Mn
Dec 31, 2009 1.94 Mn
Dec 31, 2009 1.94 Mn